Global Idiopathic Pulmonary Fibrosis Market Growth (Status and Outlook) 2023-2029

Global Idiopathic Pulmonary Fibrosis Market Growth (Status and Outlook) 2023-2029

Idiopathic pulmonary fibrosis is a condition in which the tissues in the lungs become thick and stiff over time. As a result of thickening of lung tissues, brain and other organs are unable receive optimum oxygen.

LPI (LP Information)' newest research report, the “Idiopathic Pulmonary Fibrosis Industry Forecast” looks at past sales and reviews total world Idiopathic Pulmonary Fibrosis sales in 2022, providing a comprehensive analysis by region and market sector of projected Idiopathic Pulmonary Fibrosis sales for 2023 through 2029. With Idiopathic Pulmonary Fibrosis sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Idiopathic Pulmonary Fibrosis industry.

This Insight Report provides a comprehensive analysis of the global Idiopathic Pulmonary Fibrosis landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Idiopathic Pulmonary Fibrosis portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Idiopathic Pulmonary Fibrosis market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Idiopathic Pulmonary Fibrosis and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Idiopathic Pulmonary Fibrosis.

The global Idiopathic Pulmonary Fibrosis market size is projected to grow from US$ 1694 million in 2022 to US$ 3270.8 million in 2029; it is expected to grow at a CAGR of 9.9% from 2023 to 2029.

An increase in the incidence and prevalence of fibrotic diseases is the primary driver for the growth of this market. Idiopathic pulmonary fibrosis most commonly affects middle-aged to older adults and is characterized by the scarring of lung tissues. In older people, these scars tend to build up and affect the normal functioning of lungs. Thus, an increase in aging population leads to increased prevalence of the disease, which in turn results in market growth during the predicted period.

This report presents a comprehensive overview, market shares, and growth opportunities of Idiopathic Pulmonary Fibrosis market by product type, application, key players and key regions and countries.

Market Segmentation:

Segmentation by type
Systemic Corticosteroids
Immunosuppressant Drugs
Tyrosine Kinase Inhibitors
Antifibrotic Agents

Segmentation by application
Hospitals
Clinics
Ambulatory Surgical Centers
Academic and Research Organizations

This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
MediciNova
Boehringer Ingelheim
F. Hoffmann-La Roche
FibroGen
Promedior
Merck
Galapagos
Prometic Life Sciences
Cipla

Please note: The report will take approximately 2 business days to prepare and deliver.